natgillin/translations-raw huggingface dataset:
The safety and efficacy of eltrombopag has not been established in children and adolescents (< 18 years) with chronic HCV related thrombocytopenia or SAA.
Varnost in učinkovitost eltrombopaga nista bili dokazani pri otrocih in mladostnikih, ki so stari manj kot 18 let in imajo trombocitopenijo zaradi okužbe z virusom hepatitisa C (HCV) ali hudo aplastično anemijo.
The safety and efficacy of eltrombopag in paediatric subjects has been investigated in two studies.
Varnost in učinkovitost eltrombopaga pri pediatričnih bolnikih so raziskovali v dveh študijah.
The safety and efficacy of eltrombopag in paediatric subjects has been investigated two studies.
Varnost in učinkovitost eltrombopaga pri pediatričnih bolnikih so raziskovali v dveh študijah.
The safety and efficacy of eluxadoline in children aged 0 to18 years have not yet been established.
Varnost in učinkovitost eluksadolina pri otrocih, starih od 0 do 18 let, še nista dokazani.
The safety and efficacy of emtricitabine/tenofovir disoproxil in children under the age of 18 years have not been established.
Varnost in učinkovitost emtricitabina / dizoproksiltenofovirata pri otrocih starih pod 18 let nista bili dokazani.
The safety and efficacy of emtricitabine/tenofovir disoproxil in children under the age of 18 years have not yet been established (see section 5.2).
Varnost in učinkovitost emtricitabina/dizoproksiltenofovirata pri otrocih, mlajših od 18 let, še nista bili dokazani (glejte poglavje 5.2).
The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with polyarticular- course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset) .
Varnost in učinkovitost zdravila Enbrel je bila ugotovljena v dvodelni študiji pri 69 otrocih s poliartikularnim potekom juvenilnega idiopatskega artritisa z različnimi tipi nastopa bolezni (poliartritis, oligoartritis, sistemski nastop).
The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with polyarticular- course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset).
Varnost in učinkovitost zdravila Enbrel je bila ugotovljena v dvodelni študiji pri 69 otrocih s poliartikularnim potekom juvenilnega idiopatskega artritisa z različnimi tipi nastopa bolezni (poliartritis, oligoartritis, sistemski nastop).
The safety and efficacy of enoxaparin sodium has not been established in children below the age of 12 years.
Varnost in učinkovitost natrijevega enoksaparinata pri otrocih, starih do 12 let, še nista bili dokazani.
The safety and efficacy of enoxaparin sodium in children below the age of 12 years has not been established.
Varnost in učinkovitost natrijevega enoksaparinata pri otrocih, starih do 12 let, še nista bili dokazani.
The safety and efficacy of entecavir were also evaluated in an active-controlled clinical trial of 191 HBV- infected patients with decompensated liver disease and in a clinical trial of 68 patients co-infected with HBV and HIV.
Varnost in učinkovitost entekavirja so vrednotili tudi v aktivno nadzorovanem kliničnem preskušanju, izvedenem pri 191 bolnikih, ki so bili okuženi z virusom HBV in so imeli dekompenzirano bolezen jeter, ter v kliničnem preskušanju pri 68 bolnikih, ki so bili sočasno okuženi z virusom HBV in virusom HIV.
The safety and efficacy of Envarsus in children below 18 years of age have not yet been established.
Varnost in učinkovitost zdravila Envarsus pri otrocih, starih do 18 let, še nista bili dokazani.
The safety and efficacy of Epclusa in children and adolescents aged less than 18 years have not yet been established.
Varnost in učinkovitost zdravila Epclusa pri otrocih in mladostnikih, starih manj kot 18 let, še nista bili dokazani.
The safety and efficacy of epoetin alfa in paediatric patients receiving chemotherapy have not been established.
Varnost in učinkovitost epoetina alfa pri pediatričnih bolnikih, ki prejemajo kemoterapijo, nista bili dokazani.
The safety and efficacy of Eporatio in children and adolescents aged up to 17 years have not yet been established.
Varnost in učinkovitost zdravila Eporatio pri otrocih in mladostnikih, starih do 17 let, nista bili dokazani.
The safety and efficacy of Erivedge in children and adolescents aged below 18 years have not been established..
Varnost in učinkovitost zdravila Erivedge pri otrocih in mladostnikih, mlajših od 18 let, nista ugotovljeni.
The safety and efficacy of eslicarbazepine acetate in children and adolescents below 18 years has not yet been established.
Varnost in učinkovitost zdravila Zebinix pri otrocih in mladostnikih, starih do 18 let še nista bili dokazani.
The safety and efficacy of eslicarbazepine acetate in children and adolescents below 18 years has not yet been established.
Varnost in učinkovitost zdravila Zebinix pri otrocih starih in mladostnikih, do 18 let še nista bili dokazani.
The safety and efficacy of Eucreas in children and adolescents (< 18 years) have not been established.
Varnost in učinkovitost zdravila Eucreas pri otrocih in mladostnikih (< 18 let) nista bili dokazani.
The safety and efficacy of Eviplera in children under the age of 18 years have not been established.
Varnost in učinkovitost zdravila Eviplera pri otrocih starih pod 18 let nista bili dokazani.
The safety and efficacy of Exalief below 18 years has not yet been established.
Varnost in učinkovitost zdravila Exalief pri otrocih starih do 18 let še nista bili dokazani.
The safety and efficacy of Eylea therapy administered to both eyes concurrently have not been systematically studied (see section 5.1).
Varnosti in učinkovitosti zdravljenja z zdravilom Eylea, sočasno apliciranim v obe očesi, niso sistematično preučevali (glejte poglavje 5.1).
The safety and efficacy of Eylea were assessed in a randomised, multi-centre, double-masked, active- controlled study in patients with macular oedema secondary to BRVO (VIBRANT) which included Hemi-Retinal Vein Occlusion.
Varnost in učinkovitost zdravila Eylea so ocenili v randomizirani, multicentrični, dvojno slepi, aktivno nadzorovani študiji pri bolnikih z makularnim edemom, ki nastane kot posledica BRVO (VIBRANT), vključno z delno zaporo veje mrežnične vene.
The safety and efficacy of Eylea were assessed in a randomised, multi-centre, double-masked, sham- controlled study in treatment-naïve, Asian patients with myopic CNV.
Varnost in učinkovitost zdravila Eylea so ocenili v randomizirani, multicentrični, dvojno slepi, s placebom nadzorovani študiji pri še nezdravljenih, azijskih bolnikih z miopično CNV.
The safety and efficacy of Fabrazyme in patients older than 65 years have not been established and no dosage regimen can presently be recommended in these patients.
Varnosti in učinkovitosti zdravila Fabrazyme pri bolnikih, starejših od 65 let, še niso ugotovili in zanje trenutno ne moremo priporočiti nobenega režima odmerjanja.
The safety and efficacy of Faslodex in children from birth to 18 years of age have not been established.
Varnost in učinkovitost zdravila Faslodex pri otrocih od rojstva do18. leta starosti nista bili dokazani.
The safety and efficacy of FB in pediatric population has not been established.
Varnost in učinkovitost sheme FB pri pediatrični populaciji nista ugotovljeni.
The safety and efficacy of Feraccru for the treatment of iron deficiency anaemia was studied in 128 patients (age range 18-76 years; 45 males and 83 females) with inactive to mildly active IBD (58 patients with Ulcerative Colitis [UC] and 70 patients with Crohn’s disease [CD]) and baseline Hb concentrations between 9.5 g/dL and 12 / 13 g/dL for females / males.
Varnost in učinkovitost zdravila Feraccru za zdravljenje anemije zaradi pomanjkanja železa so proučevali pri 128 bolnikih (starost od 18 do 76 let, 45 moških in 83 žensk) z neaktivno do blago aktivno KVČB (58 bolnikov z ulcerativnim kolitisom [UK] in 70 bolnikov s Crohnovo boleznijo [CB]), ki so imeli izhodiščne vrednosti Hb med 9,5 g/dL in 12/13 g/dL pri ženskah/moških.
The safety and efficacy of Fexeric in children and adolescents aged 0 to 18 years have not yet been established.
Varnost in učinkovitost zdravila Fexeric pri otrocih in mladostnikih, starih od 0 do 18 let, še nista bili dokazani.
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established.
Varnost in učinkovitost uporabe filgrastima pri bolnikih z na novo nastalo akutno mieloično levkemijo, ki so mlajši od 55 let in imajo dobro citogenetiko [t(8;21), t(15;17) in inv(16)] nista bili dokazani.
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established.
Varnost in učinkovitost uporabe filgrastima pri bolnikih z na novo nastalo AML, starih < 55 let, in dobro citogenetiko [t(8;21), t(15;17), ter inv(16)] še nista bili ugotovljeni.
The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome or chronic myelogenous leukaemia have not been established.
Varnost in učinkovitost filgrastima pri bolnikih z mielodisplastičnim sindromom ali kronično mielogeno levkemijo nista bili dokazani.
The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome, or chronic myelogenous leukaemia have not been established.
Varnost in učinkovitost dajanja filgrastima pri bolnikih z mielodisplastičnim sindromom ali kronično mielogeno levkemijo nista bili ugotovljeni.
The safety and efficacy of Firazyr in children aged 0-18 years has not been established.
Varnosti in učinkovitosti zdravila Firazyr pri otrocih, starih od 0 do 18 let, niso ugotovili.
The safety and efficacy of fondaparinux 2.5 mg has not been studied in the following groups: patients with superficial-vein thrombosis following sclerotherapy or resulting as a complication of an intravenous line, patients with history of superficial-vein thrombosis within the previous 3 months, patients with history of venous thromboembolic disease within the previous 6 months, or patients with active cancer (see section 4.2 and 5.1).
Varnost in učinkovitost 2,5 mg fondaparinuksa nista raziskani v naslednjih skupinah: pri bolnikih s povrhnjo vensko trombozo, nastalo po skleroterapiji ali kot zaplet intravenske linije, bolnikih z anamnezo povrhnje venske tromboze v preteklih 3 mesecih, bolnikih z anamnezo venske trombembolične bolezni v preteklih 6 mesecih in bolnikih z aktivnim rakom (glejte poglavji 4.2 in 5.1).
The safety and efficacy of FORSTEO in children and adolescents less than 18 years has not been established.
Varnost in učinkovitost zdravila FORSTEO pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
The safety and efficacy of GANFORT in children aged 0 to 18 years has not been established.
Varnosti in učinkovitosti zdravila GANFORT pri otrocih, starih od 0 do 18 let, niso ugotovili.
The safety and efficacy of GANFORT single-dose in children aged less than 18 years has not been established.
Varnosti in učinkovitosti zdravila GANFORT (enoodmerna oblika) pri otrocih, mlajših od 18 let, niso ugotovili.
The safety and efficacy of Gardasil 9 in women 27 years of age and older have not been studied (see section 5.1).
Varnost in učinkovitost cepiva Gardasil 9 pri ženskah, starih 27 let ali več, nista bili raziskani (glejte poglavje 5.1).
The safety and efficacy of Gazyvaro has not been established in patients with severe renal impairment (CrCl < 30 mL/min).
Varnost in učinkovitost zdravila Gazyvaro pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) nista ugotovljeni.
The safety and efficacy of Genvoya in children younger than 12 years of age, or weighing < 35 kg, have not yet been established.
Varnost in učinkovitost zdravila Genvoya pri otrocih, mlajših od 12 let, ali s telesno maso < 35 kg, še nista bili dokazani.
The safety and efficacy of Gilenya in children aged 0 to 18 years have not yet been established.
Varnost in učinkovitost zdravila Gilenya pri otrocih, starih od 0 do 18 let, še nista bili dokazani.
The safety and efficacy of Glybera in children and adolescents below 18 years has not been established.
Varnost in učinkovitost zdravila Glybera pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
The safety and efficacy of GRANUPAS in neonates have not been established.
Varnost in učinkovitost zdravila GRANUPAS pri novorojenčkih še ni bila dokazana.
The safety and efficacy of Grastofil are similar in adults and children receiving cytotoxic chemotherapy.
Varnost in učinkovitost zdravila Grastofil sta podobni pri odraslih in otrocih, ki dobivajo citotoksično kemoterapijo.
The safety and efficacy of Humira in children aged 12-17 years have not yet been established for hidradenitis suppurativa.
Varnost in učinkovitost zdravila Humira pri otrocih, starih 12-17 let, za hidradenitis suppurativa ni bila potrjena.
The safety and efficacy of Humira in children aged 2-17 years have not yet been established.
Varnost in učinkovitost zdravila Humira pri otrocih starih 2-17 let nista bili dokazani.
The safety and efficacy of Humira was assessed in an open-label, multicenter study in 32 children (2 - < 4 years old or aged 4 and above weighing < 15 kg) with moderately to severely active polyarticular JIA.
Varnost in učinkovitost zdravila Humira so ocenili v odprti, multicentrični študiji pri 32 otrocih (starih od 2 do < 4 leta ali starih 4 leta ali več in s telesno maso < 15 kg) z zmernim do zelo aktivnim poliartikularnim JIA.
The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types (most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).
Varnost in učinkovitost zdravila Humira so ocenili v dveh študijah (pJIA I in II) pri otrocih z aktivnim poliartikularnim ali poliartikularnim juvenilnim idiopatskim artritisom, z različnimi tipi začetka JIA (najpogosteje negativen revmatoidni faktor ali pozitiven poliartritis in razširjen oligoartritis).
The safety and efficacy of Humira were also studied in adult patients with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-blind study (Psoriasis Study III).
Varnost in učinkovitost zdravila Humira so raziskali tudi v randomizirani dvojno slepi študiji pri odraslih bolnikih z zmerno do hudo kronično psoriazo v plakih s sočasno psoriazo na dlaneh in/ali stopalih, ki so bili kandidati za sistemsko zdravljenje (Študija pri psoriazi III).
The safety and efficacy of Humira were assessed in a multicenter, randomised, double-blind study in 46 paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis.
Varnost in učinkovitost zdravila Humira so ocenili v multicentrični, randomizirani, dvojno slepi študiji pri 46 pediatričnih bolnikih (starih od 6 do 17 let) z zmernim artritisom, povezanim z entezitisom.
The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double- masked, placebo-controlled studies (UV I and II).
Varnost in učinkovitost zdravila Humira sta bili ocenjeni pri odraslih bolnikih z neinfekcijskim intermediarnim, posteriornim uveitisom in panuveitisom v dveh randomiziranih, dvojno slepih, s placebom kontroliranih študijah (UV I in UV II), ki nista vključevali bolnikov z izoliranim anteriornim uveitisom.
The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active Crohn’s disease (Crohn’s Disease Activity Index (CDAI)  220 and  450) in randomised, double-blind, placebo-controlled studies.
Varnost in učinkovitost zdravila Humira so ocenili pri več kot 1500 bolnikih z zmerno do zelo aktivno Crohnovo boleznijo (indeks aktivnosti Crohnove bolezni [CDAI]  220 in  450) v randomiziranih, dvojno slepih, s placebom kontroliranih študijah.
The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active Crohn’s disease (Crohn’s Disease Activity Index (CDAI)  220 and  450) in randomised, double-blind, placebo-controlled studies.
Varnost in učinkovitost zdravila Humira so ovrednostili pri preko 1500 bolnikih z zmerno do hudo aktivno Crohnovo boleznijo (Crohn’s Disease Activity Index (CDAI) ≥ 220 in ≤ 450) v randomizirani, dvojno slepi, s placebom kontrolirani študiji.
The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a 3- month trial of systemic antibiotic therapy.
Varnost in učinkovitost zdravila Humira so raziskali v randomiziranih, dvojno slepih študijah, kontroliranih s placebom in v odprti podaljšani študiji pri odraslih bolnikih z zmerno do hudo obliko hidradenitis suppurativa (HS), ki imajo intoleranco, kontraindikacijo ali se ne odzovejo zadovoljivo pri vsaj 3-mesečnem preskušanju sistemske antibiotične terapije.
The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis ( 10% BSA involvement and PASI  12 or  10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies.
Varnost in učinkovitost zdravila Humira so raziskali v randomiziranih, dvojno slepih študijah pri odraslih bolnikih s kronično psoriazo v plakih (zajete  10 % telesne površine ter indeksom obsežnosti in izrazitosti psoriaze PASI  12 ali  10), ki so bili kandidati za sistemsko zdravljenje ali fototerapijo.
The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis ( 10% BSA involvement and Psoriasis Area and Severity Index (PASI)  12 or  10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies.
Varnost in učinkovitost zdravila Humira so v randomiziranih, dvojno slepih študijah raziskali pri odraslih bolnikih s kronično psoriazo v plakih (zajete  10 % telesne površine ter indeksom obsežnosti in izrazitosti psoriaze (PASI – Psoriasis Area and Severity Index)  12 ali  10), ki so bili kandidati za sistemsko zdravljenje ali fototerapijo.
The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis ( 10% BSA involvement and Psoriasis Area and Severity Index (PASI)  12 or  10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies.
Varnost in učinkovitost zdravila Humira so v randomiziranih, dvojno slepih študijah raziskali pri odraslih bolnikih s kronično psoriazo v plakih (zajete  10% telesne površine ter indeksom obsežnosti in izrazitosti psoriaze (PASI – Psoriasis Area and Severity Index)  12 ali  10), ki so bili kandidati za sistemsko zdravljenje ali fototerapijo.
The safety and efficacy of Iasibonin children and adolescents below the age of 18 years have not been established.
Varnost in učinkovitost zdravila Iasibon pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
The safety and efficacy of Ibandronic Acid Teva in children and adolescents below the age of 18 years have not been established.
Varnost in učinkovitost zdravila Ibandronska kislina Teva pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
The safety and efficacy of IDELVION in previously untreated patients have not yet been established.
Varnost in učinkovitost zdravila IDELVION pri predhodno nezdravljenih bolnikih še nista bili dokazani.
The safety and efficacy of IM olanzapine has not been evaluated in patients with alcohol or drug intoxication (either with prescribed or illicit drugs) (see section 4.5).
Varnosti in učinkovitosti i.m. olanzapina pri bolnikih z zastrupitvijo z alkoholom, zdravili (predpisanimi) ali nedovoljenimi drogami niso vrednotili (glejte poglavje 4.5).
The safety and efficacy of imatinib in children with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Varnost in učinkovitost uporabe imatiniba pri otrocih, ki imajo MDS/MPD, DFSP ali HES/CEL in so stari manj kot 18 let, nista bili dokazani v kliničnih preskušanjih.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Varnost in učinkovitost uporabe imatiniba pri otrocih, ki imajo MDS/MPD, DFSP in HES/CEL in so stari manj kot 18 let, nista bili dokazani v kliničnih preskušanjih.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP, GIST and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Varnost in učinkovitost uporabe imatiniba pri otrocih, ki imajo MDS/MPD, DFSP, GIST ali HES/CEL in so stari manj kot 18 let, nista bili dokazani v kliničnih preskušanjih.
The safety and efficacy of IMBRUVICA in children aged 0 to 18 years have not been established.
Varnost in učinkovitost zdravila IMBRUVICA pri otrocih, starih od 0 do 18 let, nista bili dokazani.
The safety and efficacy of IMBRUVICA in patients previously treated for CLL were further evaluated in a randomised, multicenter, double-blinded phase 3 study of IMBRUVICA in combination with BR versus placebo + BR (Study CLL3001).
Varnost in učinkovitost zdravila IMBRUVICA pri bolnikih, predhodno zdravljenih za KLL so ocenjevali tudi v randomizirani, multicentrični, dvojno slepi študiji faze 3, kjer so primerjali zdravilo IMBRUVICA v kombinaciji z BR in kombinacijo placebo + BR (študija CLL3001).
The safety and efficacy of imiquimod in actinic keratosis in children and adolescents below the age of 18 years have not been established.
Varnost in učinkovitost imikvimoda pri aktinični keratozi pri otrocih in mladostnikih, starih do 18 let, še nista bili dokazani.
The safety and efficacy of Imlygic monotherapy compared with subcutaneously administered GM- CSF were evaluated in a phase 3, multinational, open-label, and randomised clinical study of patients with stage IIIB, IIIC, and IV melanoma that was not considered to be surgically resectable.
Varnost in učinkovitost monoterapije z zdravilom Imlygic v primerjavi s subkutano uporabljenim GM-CSF so ocenili v mednarodni, odprti, randomizirani klinični študiji 3. faze pri bolnikih z melanomom stopenj IIIB, IIIC in IV, ki je bil ocenjen kot inoperabilen.
The safety and efficacy of immunization with any vaccine, particularly live viral vaccines, following therapy with Zevalin have not been studied (see also section ‘Special warnings and precautions for use’).
Študij varnosti in učinkovitosti imunizacije s katerimkoli cepivom, zlasti z živimi virusnimi cepivi, po zdravljenju z zdravilom Zevalin niso izvedli (glejte tudi poglavje Posebna opozorila in previdnostni ukrepi).
The safety and efficacy of IMVANEX in individuals below 18 years of age have not been established.
Varnost in učinkovitost cepiva IMVANEX pri posameznikih, starih manj kot 18 let, nista bili dokazani.
The safety and efficacy of INCIVO in children aged < 18 years have not yet been established.
Varnosti in učinkovitosti zdravila INCIVO pri otrocih, starih < 18 let niso ugotovili.
The safety and efficacy of INCRELEX in children below age of 2 have not been established.
Varnost in učinkovitost zdravila INCRELEX pri otrocih, mlajših od 2 let, nista bili dokazani.
The safety and efficacy of InductOs have not been established in the following conditions: used with interbody fusion devices made from material other than titanium, PEEK or bone
Varnosti in učinkovitosti zdravila InductOs niso ugotovili v naslednjih okoliščinah: pri uporabi vsadkov za interkorpusno fuzijo, narejenih iz drugih materialov, razen iz titana, PEEK ali kosti;
The safety and efficacy of Inflectra have not been studied in children with Crohn’s disease below the age of 6 years.
Varnosti in učinkovitosti zdravila Inflectra pri otrocih s Crohnovo boleznijo, mlajših od 6 let, niso preučevali.